Update: I injected myself with Aimovig (erenumab) and here’s what happened so far

June 10, 2018

On June 1, I injected myself with erenumab (Aimovig). I still had to take sumatriptan for an incipient migraine on June 2 and June 5. On Thursday, June 7, I had a glass of red wine (pinot noir) with dinner and had no headache. Last night, June 9, I decided to stress-test my response to erenumab and had a beer before dinner and a big glass of sparkling wine with dinner. In the past, this combination had always resulted in a migraine a few hours later. This time, nothing happened!

And here is an excerpt from an email from a patient who was one of the first to receive Aimovig:

“Hello Doctor,
It has been a week now and I wanted to share with you the outcome.
It’s a very important improvement as I was able to stop taking Relpax compared to 40mg a day!
3-4 times I felt the migraine coming but it was like « stopped » and I was feeling ok.
It happened during the day and at night twice.
Overall it’s a fantastic improvement.”

Certainly, this all could be due to the placebo effect, but I doubt it, especially because my migraines did not stop right after the injection. I should stress that erenumab is not going to help everyone. Clinical trials suggest that about 60% of migraine sufferers will benefit, but this is a very high success rate, especially considering the lack of any significant side effects.

Cheers!

Written by
Alexander Mauskop, MD
Continue reading
March 26, 2026
Alternative Therapies
Lidocaine-Based Treatments Offer Another Option for Severe Migraines
This post explains how lidocaine, beyond its traditional use as a local anesthetic, can be given by IV or directly into the middle meningeal artery to help break severe, treatment-resistant migraines, with early studies showing promising relief and generally mild, manageable side effects.
Read article
February 16, 2026
News
Potential big news for the 40 million Americans with migraine.
It is long overue to make triptans available without a prescription, like in the rest of the world.
Read article